PPT-My Experiences as an FDA Statistician

YehFong Chen PhD FDACDEROBDB3 CBA 20162017 Workshop series3 Dec 18 2016 Disclaimer This presentation reflects the views of the author and should not be construed to represent the views or policies of the US Food and Drug Administration. The American Statistician 1061 Rockville MD 20852 All comments should be identified with the docket number listed in the notice of availability that is published in the Federal Register For questions rega rding this document contact Michael Ortwerth at 301 796 8220 US Depart and. IRB Inspections. VA IRB Chairs Meeting. August 2012. Janet Donnelly RAC, CIP. Office of Good Clinical Practice . Office of the Commissioner. Food and Drug Administration . 2. 2. Disclaimer. The views expressed in this presentation are those of the speaker and is consistent with 21 CFR 10.85 (k) and constitutes an informal communication that represents the presenter's best judgment at this time but does not constitute an advisory opinion, does not necessarily represent the formal position of FDA, and does not bind or otherwise obligate or commit the agency to the views expressed. . MARCH 2011 Consumer Health Information www.fda.gov/consumer FDA Intends to Remove Unapproved Drugs from Market F DA announced Wednesday remove certain unapproved prescription medicines intended Bruce Ross. , . M.A. M.P.H.. Director, India Office. Agenda. Priorities. Challenges of globalization. cGMP. . deficiencies. Comparison. Post inspection regulatory . actions. 2. Advance Regulatory Science: the science of developing new tools, standards and approaches to assess the safety and effectiveness, quality and performance of FDA-regulated products. James C. Shehan. Hyman, Phelps & McNamara, P.C.. 700 Thirteenth Street, N.W., Suite 1200. Washington, D.C. 20005, U.S.A.. 202-737-9634 .  . jshehan@hpm.com. October 29, 2014. Agenda. BPCIA Overview. Jeff Shuren, MD, JD. Center for Devices and Radiological Health. U.S. Food and Drug Administration. Patients are at the Heart of What We Do. CDRH Vision: Patients in the U.S. have access to high-quality, safe, and effective medical devices of public health importance first in the world . Products - 2009 . Tobacco Control Act. - Regulate cigarettes and smokeless . t. obacco . p. roducts . - Ban tobacco-brand . sponsorships of . sports & entertainment . - Ban . free . giveaways. Vivek Y. Reddy MD. 1. *, Douglas N. Gibson MD. 2. , . Saibal. Kar. 3. , William O’Neill MD. 4. , . Shephal. K. . Doshi. MD. 5. , Rodney P. Horton MD. 6. , Maurice . Buchbinder. MD. 7. , Nicole T. Gordon BSEE. SUPPLEMENTAL MATERIAL. Version: 12-7-17. Business Size. Compliance Dates. For Most Produce. Proposed . Water Related Compliance. Dates. All. other. businesses (>$500K). 1/26/18. 1/26/22. Small businesses . For innovation to be successful, it needs to be more than just a buzz word.. www.fda.gov. Why Innovation?. WHY innovation?. Why Innovation?. 42% of millennials are . leaving . jobs because of substandard . Division of Human Food Safety. Office of New Animal Drug Evaluation. Center for Veterinary Medicine. US Food and Drug Administration. Human Food Safety of New Animal Drugs: . Toxicology Assessment. 6/14/2012. Investigational New Drug Application (IND); Summary of regulations and guidelines . Introduction of . cGMP's. /principles of validation . Introduction to QA/QC principles . Good Laboratory Practice (GLP) compliance . precision.fda.gov | precisionFDA@fda.hhs.gov | @precisionFDA. Taha A. Kass-Hout, MD, MS. FDA Chief Health Informatics . Officer. Director, FDA’s Office of Health . Informatics. David . Litwack. , PhD.